title: Budesonide and prednisolone suppress peripheral blood natural killer cells in Crohn's disease.
abstract: OBJECTIVE
  To study the effect of oral budesonide and prednisolone on peripheral blood natural killer (NK) cell activity in patients with active ileocaecal Crohn's disease (Crohn's disease activity index, CDAI > or = 200).
  
  
  METHODS
  One group of patients was treated for 10 weeks with oral budesonide (n = 9; 9 mg/day), and another group of patients for the same period with prednisolone (n = 9; 40 mg/day). Budesonide was tapered to 6 mg/day after 8 weeks and prednisolone after 2 weeks to 5 mg/day in the last week. Before treatment, and at 2, 4 and 10 weeks of treatment, natural killer cell activity was determined with a 51Cr release assay, and the number of CD16+ NK cells by Fluorescence activated cell sorter (FACS) analysis.
  
  
  RESULTS
  Budesonide, as well as prednisolone treatment, significantly decreased natural killer cell activity at weeks 2 and 4. This decrease was found to be accompanied by a similar decrease in the number of CD16+ NK cells. At 10 weeks, natural killer cell activity had almost returned to pre-treatment levels in the budesonide group and was significantly higher than pre-treatment levels in the prednisolone group. Disease activity was significantly decreased in all patients at week 2 until the end of the trial period.
  
  
  CONCLUSIONS
  Both budesonide and prednisolone treatment suppress peripheral blood natural killer cell activity of patients with active ileocaecal Crohn's disease by decreasing the numbers of CD16+ NK cells in the circulation.
authors.affiliation: Department of Gastroenterology and Hepatology, University Hospital Leiden, The Netherlands.
authors.forename: A J
authors.initials: AJ
authors.lastname: Van Ierssel
authors.forename: A
authors.initials: A
authors.lastname: Van der Sluys Veer
authors.forename: H W
authors.initials: HW
authors.lastname: Verspaget
authors.forename: G
authors.initials: G
authors.lastname: Griffioen
authors.forename: R A
authors.initials: RA
authors.lastname: Van Hogezand
authors.forename: C B
authors.initials: CB
authors.lastname: Lamers
mesh_terms: D000328:Adult; D019819:Budesonide; D002452:Cell Count / Q000187:drug effects; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology; D003601:Cytotoxicity Tests, Immunologic; D004305:Dose-Response Relationship, Drug; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000276:immunology; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use*; D011282:Pregnenediones / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D011282:Pregnenediones; D019819:Budesonide; D011239:Prednisolone